Robinson A, Irons L I, Ashworth L A
Vaccine. 1985 Mar;3(1):11-22. doi: 10.1016/0264-410x(85)90004-0.
Use of killed whole-cell Bordetella pertussis vaccines has been a major factor in control of symptomatic whooping cough (pertussis). In the UK, diminished public confidence in the safety of this vaccine led to a reduction in vaccine acceptance which correlated with an increase in the incidence of pertussis. There is a need for acellular pertussis vaccines of low toxicity which, ideally, will prevent colonization and also protect against the disease symptoms. Vaccine design can rely increasingly on knowledge of the roles of individual bacterial components in the pathogenesis of pertussis. Serotype-specific agglutinogens 2 and 3 (fimbriae) and filamentous haemagglutinin are among surface components of B. pertussis which probably mediate adhesion to the respiratory mucosa. Systemic effects of pertussis can largely be attributed to the lymphocytosis promoting factor (pertussis toxin). Vaccines containing detoxified toxin plus one or more purified adhesins are envisaged at present.
使用全细胞百日咳博德特氏菌灭活疫苗一直是控制有症状百日咳（pertussis）的主要因素。在英国，公众对该疫苗安全性的信心下降导致疫苗接种率降低，这与百日咳发病率上升相关。需要低毒性的无细胞百日咳疫苗，理想情况下，这种疫苗能预防细菌定植并预防疾病症状。疫苗设计越来越依赖于对百日咳发病机制中各个细菌成分作用的了解。血清型特异性凝集原2和3（菌毛）以及丝状血凝素是百日咳博德特氏菌的表面成分，它们可能介导细菌与呼吸道黏膜的黏附。百日咳的全身效应很大程度上可归因于淋巴细胞增多促进因子（百日咳毒素）。目前设想的疫苗是含有解毒毒素以及一种或多种纯化黏附素的疫苗。
